Equities

Silo Pharma Inc

SILO:NAQ

Silo Pharma Inc

Actions
Consumer DiscretionaryConsumer Discretionary
  • Price (USD)1.06
  • Today's Change0.04 / 3.92%
  • Shares traded49.18k
  • 1 Year change-43.92%
  • Beta1.4753
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Silo Pharma Inc share price to rise to 10.00 in the next year from the last price of 1.02.
High880.4%10.00
Med880.4%10.00
Low880.4%10.00

Earnings history & estimates in USD

On Mar 25, 2024, losses of -0.36 per share.
Silo Pharma Inc reported annual 2023 losses of -1.18 per share on Mar 25, 2024.
More ▼

Revenue history & estimates in USD

of 18.00k. This equaled the revenue expectation of the one analyst following the company. The same period last year the company did not report revenues.
Uppercut Brands Inc. had revenues for the full year 2023 of 72.00k. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.